TECH vs. RGEN, QGEN, EXEL, NBIX, PCVX, RVMD, CRSP, HALO, KRYS, and IMVT
Should you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Repligen (RGEN), Qiagen (QGEN), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Vaxcyte (PCVX), Revolution Medicines (RVMD), CRISPR Therapeutics (CRSP), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), and Immunovant (IMVT). These companies are all part of the "biological products, except diagnostic" industry.
Repligen (NASDAQ:RGEN) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
97.6% of Repligen shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 1.2% of Repligen shares are held by company insiders. Comparatively, 4.5% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Bio-Techne has a net margin of 19.58% compared to Bio-Techne's net margin of 6.51%. Repligen's return on equity of 14.21% beat Bio-Techne's return on equity.
Repligen received 14 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 68.03% of users gave Repligen an outperform vote while only 62.36% of users gave Bio-Techne an outperform vote.
Repligen has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.
In the previous week, Bio-Techne had 2 more articles in the media than Repligen. MarketBeat recorded 8 mentions for Bio-Techne and 6 mentions for Repligen. Bio-Techne's average media sentiment score of 0.94 beat Repligen's score of 0.62 indicating that Repligen is being referred to more favorably in the media.
Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Repligen presently has a consensus target price of $196.70, indicating a potential upside of 17.82%. Bio-Techne has a consensus target price of $83.90, indicating a potential upside of 31.30%. Given Repligen's higher probable upside, analysts clearly believe Bio-Techne is more favorable than Repligen.
Summary
Bio-Techne beats Repligen on 11 of the 17 factors compared between the two stocks.
Get Bio-Techne News Delivered to You Automatically
Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Techne Competitors List
Related Companies and Tools
